Clinical Trials
MCED trial finds no significant reduction in late-stage cancer diagnoses
LawrenceCancer

Multicancer early detection (MCED) testing has emerged as a novel screening modality intended to identify asymptomatic malignancies at earlier, potentially more treatable stages. However, trial data evaluating the clinical utility of MCED testing demonstrate that while screening increased the detection of early-stage cancers, it did not lead to a statistically significant decrease in late-stage cancer diagnoses. \n\nBecause a reduction in late-stage presentations is a crucial intermediate benchmark for establishing cancer screening efficacy and downstream mortality benefits, the absence of a significant decline in advanced disease raises critical concerns regarding the clinical implementation and true screening value of current MCED assays.
Key Takeaways
- Multicancer early detection testing successfully increased the rate of early-stage cancer detection.
- Multicancer early detection testing failed to significantly reduce late-stage cancer diagnoses, challenging its anticipated clinical utility for stage shifting.
Read the original sourceCancer
